Pharsight

1. Drug name - ACTONEL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938	APIL	Method of treatment using bisphosphonic acid	May, 2023 (6 months from now)
US7718634	APIL	Method of treatment using bisphosphonic acid	May, 2023 (6 months from now)
US7718634 (Pediatric)	APIL	Method of treatment using bisphosphonic acid	Nov, 2023 (1 year, 1 month from now)
US7192938 (Pediatric)	APIL	Method of treatment using bisphosphonic acid	Nov, 2023 (1 year, 1 month from now)

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
35MG	TABLET;ORAL	Prescription
75MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
150MG	TABLET;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989	APIL	Dosage forms of bisphosphonates	Jan, 2026 (3 years from now)
US7645459	APIL	Dosage forms of bisphosphonates	Jan, 2028 (5 years from now)
US7645460	APIL	Dosage forms of risedronate	Jan, 2028 (5 years from now)

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
35MG	TABLET, DELAYED RELEASE;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779	APIL	Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation	Oct, 2025 (2 years from now)

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.01MG,0.01MG;1MG,N/A	TABLET;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET;ORAL

Strength	Dosage	Availability
0.01MG,0.01MG,N/A;1MG,N/A,N/A	TABLET, CHEWABLE, TABLET;ORAL	Discontinued